Genelux Stock (NASDAQ:GNLX)


RevenueFinancialsChart

Previous Close

$2.46

52W Range

$1.60 - $16.60

50D Avg

$2.64

200D Avg

$3.49

Market Cap

$88.07M

Avg Vol (3M)

$179.32K

Beta

-3.17

Div Yield

-

GNLX Company Profile


Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

24

IPO Date

Jan 26, 2023

Website

GNLX Performance


GNLX Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income---
Net Income---
EBITDA---
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
DYAIDyadic International, Inc.
CGEMCullinan Oncology, Inc.
MNPRMonopar Therapeutics Inc.
IVAInventiva S.A.
CNTACentessa Pharmaceuticals plc
IKNAIkena Oncology, Inc.
LRMRLarimar Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
CINGCingulate Inc.
TERNTerns Pharmaceuticals, Inc.
MLTXMoonLake Immunotherapeutics
GLUEMonte Rosa Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.
NAMSNewAmsterdam Pharma Company N.V.
IMRXImmuneering Corporation
CELCCelcuity Inc.
CMPXCompass Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals, Inc.